S121: REDUCED RATE OF VASO-OCCLUSIVE CRISES (VOCS) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD) TREATED WITH CRIZANLIZUMAB FOR 12 MONTHS: RESULTS FROM A REAL-WORLD, MANAGED ACCESS PROGRAM (MAP)

Detalles Bibliográficos
Autores principales: Silva-Pinto, A, Colombatti, R, Pasanisi, A, Arcioni, F, DeBonnett, L, Soliman, W, Sarkar, R, Cançado, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Oral Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812129/
http://dx.doi.org/10.1097/01.HS9.0000821452.65842.6a

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812129/
http://dx.doi.org/10.1097/01.HS9.0000821452.65842.6a

Ejemplares similares